-
Biocon Share Price in Focus as Its Pertuzumab Becomes the First Biosimilar to Win EMA Backing
- September 21, 2026
- Posted by: Harsh Piplani
- Category: News
No Comments
Biocon share price is in focus after its Pertuzumab biosimilar, Pebrilzo, became the first such biosimilar to secure a positive CHMP opinion from the EMA.
